Poxel reports top-line results from Phase IIb trial of imeglimin in Japan

French biopharmaceutical firm Poxel has reported positive top-line results from its Phase IIb clinical trial of imeglimin in Japan to treat patients with type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news